Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients ...

4 analysts have shared their evaluations of Collegium Pharmaceutical COLL during the recent three months, expressing a mix of bullish and bearish perspectives. The table below provides a snapshot ...

Collegium Charter School contains 1 schools and 2,861 students. The district’s minority enrollment is 60%. Also, 45.8% of students are economically disadvantaged. The student body at the schools ...

STOUGHTON, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) (the “Company”), a leading, diversified specialty pharmaceutical company committed to ...

The most recent trading session ended with Collegium Pharmaceutical (COLL) standing at $38.79, reflecting a -1.6% shift from the previouse trading day's closing. The stock's performance was behind ...

STOUGHTON, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of ...

The Supreme Court Registry has refused to accept a petition to end the Collegium system of judicial appointments and revive the National Judicial Appointments Commission (NJAC), seeking to ...

Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Benzinga is an innovative financial news outlet that has ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...